Müçteba Enes Yayla

Dr. Müçteba Enes Yayla

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2019 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
MYMüçteba Enes Yayla
Müçteba Enes Yayla
UİUfuk İlgen
Ufuk İlgen
IOİlyas Ercan Okatan
İlyas Ercan Okatan
EUEmine UsluYurteri
Emine UsluYurteri
MTMurat Torgutalp
Murat Torgutalp
AAAşkın Ateş
Aşkın Ateş

27 April 2021 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
DSDidem Sahin
Didem Sahin
MTMurat Torgutalp
Murat Torgutalp
SBserdar baysal
serdar baysal
ACAnil Colaklar
Anil Colaklar
SSSerdar Sezer
Serdar Sezer
AAAskin Ates
Askin Ates

22 November 2016 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
UİUfuk İlgen
Ufuk İlgen
MYMüçteba Enes Yayla
Müçteba Enes Yayla
NDNurşen Düzgün
Nurşen Düzgün

1 March 2022 in Joint Bone Spine
Verified
Journal Article
Closed access
MTMurat Torgutalp
Murat Torgutalp
DSDidem Sahin
Didem Sahin
SSSerdar Sezer
Serdar Sezer
MYMüçteba Enes Yayla
Müçteba Enes Yayla
GKGokturk Karatas
Gokturk Karatas
AAAskin Ates
Askin Ates

19 October 2017 in Lupus
Verified
Journal Article
Closed access
UİUfuk İlgen
Ufuk İlgen
MYMüçteba Enes Yayla
Müçteba Enes Yayla
AAA Ateş
A Ateş
IOİe Okatan
İe Okatan
EYE U Yurteri
E U Yurteri
GKG Kınıklı
G Kınıklı
Objectives: The aim of this study was to investigate the association between antiphospholipid antibodies and non-thrombotic and non-gestational manifestations of systemic lupus erythematosus. Methods: Systemic lupus erythematosus patients with persistently positive antiphospholipid antibodies or lupus anticoagulant were identified and grouped as systemic lupus erythematosus with antiphospholipid syndrome (SLE-APS), systemic lupus erythematosus with positive antiphospholipid antibodies/lupus anticoagulant without antiphospholipid syndrome (SLE-aPL), and systemic lupus erythematosus with negative aPLs (SLE-No aPL). Groups were compared in terms of non-thrombotic systemic lupus erythematosus manifestations and laboratory features retrospectively. Results: A total of 150 systemic lupus erythematosus patients, 26 with SLE-APS, 25 with SLE-aPL, and 99 with SLE-No aPL, were identified. Livedo reticularis, neurologic involvement, and thrombocytopenia were more common in antiphospholipid antibody positive systemic lupus erythematosus cases. Malar rash, arthritis, and pleuritis were more common in the SLE-No aPL, SLE-APS, and SLE-aPL groups, respectively. Positivity rates and titers of specific antiphospholipid antibodies did not differ between the SLE-APS and SLE-aPL groups. Conclusions: Presence of antiphospholipid syndrome or persistent antiphospholipid antibodies may be related to non-thrombotic and non-gestational systemic lupus erythematosus manifestations. Patients with systemic lupus erythematosus plus antiphospholipid syndrome and persistent antiphospholipid antibodies without antiphospholipid syndrome also differ in terms of systemic lupus erythematosus manifestations.

27 March 2020 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
MYMüçteba Enes Yayla
Müçteba Enes Yayla
ZKZehra Karaman
Zehra Karaman
MTMurat Torgutalp
Murat Torgutalp
ADAyşe Bahar Keleşoğlu Dinçer
Ayşe Bahar Keleşoğlu Dinçer
EGEmine Gözde Aydemir Gülöksüz
Emine Gözde Aydemir Gülöksüz
AAAşkın Ateş
Aşkın Ateş